GO:0050482 arachidonate secretion: Lipid Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050482 arachidonate secretion describes the controlled release of arachidonic acid from a cell or tissue.
• Arachidonic acid release is often the rate-limiting step for prostaglandin and leukotriene synthesis, linking this process to inflammation and immune regulation.
• Secreted arachidonate and its metabolites influence diverse physiological events, including gut microbiota development, mucus secretion, and amyloid precursor protein processing.
• Glucocorticoids suppress arachidonate metabolism and prostaglandin secretion, highlighting the endocrine control of this pathway.
• SNARE proteins mediate membrane fusion events required for milk secretion, a process that can involve arachidonate release.
• Macrophage lysosomal enzyme secretion is regulated by arachidonate metabolites, divalent cations, and cyclic AMP, showing the broad impact of this pathway on secretory functions.
Description
Arachidonate secretion (GO:0050482) is the biological process by which arachidonic acid, a polyunsaturated omega-6 fatty acid, is released from a cell or tissue in a controlled manner. This process is central to lipid signaling because free arachidonic acid serves as the precursor for eicosanoids such as prostaglandins, thromboxanes, and leukotrienes, which modulate inflammation, immunity, and tissue homeostasis. Researchers study arachidonate secretion to understand how cells regulate the availability of this key lipid mediator and how dysregulation contributes to disease. The process is not merely a passive diffusion event; it is tightly controlled by enzymatic and secretory machinery, including phospholipases and SNARE-mediated membrane fusion. In human milk, arachidonic acid is a major component, and its delivery to the infant gut influences the developing microbiome and immune system. Thus, arachidonate secretion sits at the intersection of nutrition, immunology, and cell biology.
arachidonate secretion At A Glance
| GO ID | GO:0050482 |
|---|---|
| GO term | arachidonate secretion |
| Ontology | biological_process |
| Synonym | arachidonic acid secretion |
| Major function | Controlled release of arachidonic acid from cells or tissues |
| Related processes | Eicosanoid biosynthesis, prostaglandin secretion, inflammatory response |
| Cellular context | Secretory cells, macrophages, mammary epithelial cells, respiratory epithelium |
| Regulatory inputs | Glucocorticoids, cyclic AMP, divalent cations, SNARE proteins |
What Is GO:0050482?
According to the Gene Ontology, arachidonate secretion (GO:0050482) is defined as the controlled release of arachidonic acid from a cell or a tissue. This encompasses the regulated export of free arachidonic acid, which can occur through membrane transport or as part of secretory vesicle fusion, and it is distinct from the intracellular release of arachidonate from phospholipids by phospholipases. The term is a biological process and is synonymous with arachidonic acid secretion.
Why Is arachidonate secretion Important in Cell Biology?
Arachidonate secretion is critically important because it governs the extracellular availability of arachidonic acid, the precursor to a vast array of lipid mediators that control inflammation, pain, fever, and immune responses. Dysregulated arachidonate release has been implicated in chronic inflammatory diseases, and the process is a target of anti-inflammatory drugs such as glucocorticoids. Beyond inflammation, arachidonate secretion influences infant gut microbiome development through breast milk components, affects respiratory mucus secretion, and modulates amyloid precursor protein processing in Alzheimer's disease models. Understanding this process is therefore essential for researchers in immunology, neuroscience, and nutrition.
• Provides arachidonic acid for prostaglandin and leukotriene synthesis, key mediators of inflammation.
• Glucocorticoids suppress arachidonate metabolism and prostaglandin secretion, linking stress hormones to lipid signaling.
• Breast milk-derived arachidonic acid influences infant gut dysbiosis and atopic dermatitis onset.
• Arachidonate metabolites affect secretion of an N-terminal fragment of Alzheimer's amyloid precursor protein.
• Macrophage lysosomal enzyme secretion is regulated by arachidonate metabolites, divalent cations, and cyclic AMP.
• SNARE proteins mediate milk secretion, a process that can involve arachidonate release.
• Human respiratory mucus secretion is influenced by arachidonate and its metabolites.
• Gastroprotection mechanisms involve arachidonate metabolites and prostaglandin secretion.
• Arachidonic acid is a major component of human milk, affecting infant development.
• The process is a potential therapeutic target for inflammatory and metabolic disorders.
What Happens During arachidonate secretion?
Mobilization of Arachidonic Acid from Membrane Phospholipids
In simple terms: First, arachidonic acid is cut out of the cell membrane.
Arachidonic acid is stored esterified in the sn-2 position of membrane phospholipids. Upon cellular activation, phospholipase A2 enzymes hydrolyze these bonds to liberate free arachidonic acid. This step is often the rate-limiting step for eicosanoid production and is a prerequisite for secretion. The released arachidonate can then be directed toward secretory pathways.
Intracellular Transport and Vesicular Packaging
In simple terms: The free arachidonic acid is carried to the cell surface or into vesicles for release.
Once liberated, arachidonic acid can be transported intracellularly by fatty acid-binding proteins or remain associated with membranes. In specialized secretory cells, such as mammary epithelial cells, arachidonate may be packaged into secretory vesicles that fuse with the plasma membrane via SNARE proteins. This vesicular route allows for regulated secretion in response to specific stimuli.
Membrane Fusion and Extracellular Release
In simple terms: The vesicles merge with the cell membrane and release arachidonic acid outside.
The final step of arachidonate secretion involves fusion of secretory vesicles with the plasma membrane, a process mediated by SNARE proteins such as syntaxins and SNAPs. This fusion event releases the vesicular contents, including arachidonic acid, into the extracellular space. In some cells, arachidonate may also be exported directly across the plasma membrane by transporters, though the molecular identity of such transporters is less defined.
Regulation by Hormones and Second Messengers
In simple terms: Hormones and signaling molecules can turn arachidonate secretion up or down.
Glucocorticoids inhibit arachidonate metabolism and prostaglandin secretion, demonstrating endocrine suppression of this pathway. Conversely, cyclic AMP and divalent cations modulate macrophage lysosomal enzyme secretion, which is influenced by arachidonate metabolites. These regulatory inputs ensure that arachidonate secretion is tightly controlled in response to physiological demands.
Downstream Signaling and Metabolic Fate
In simple terms: Once outside, arachidonic acid is converted into signaling molecules that affect other cells.
Secreted arachidonic acid can be taken up by neighboring cells or act locally. It is rapidly converted by cyclooxygenases and lipoxygenases into prostaglandins, thromboxanes, and leukotrienes, which exert diverse biological effects. In the gut, milk-derived arachidonic acid influences the infant microbiome and immune development. In the brain, arachidonate metabolites affect amyloid precursor protein processing.
Key Genes Involved in GO:0050482 arachidonate secretion
The following genes and proteins are experimentally implicated in arachidonate secretion and its regulatory network, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PLA2G4A | Phospholipase A2, liberates arachidonic acid from phospholipids | Rate-limiting enzyme for arachidonate release |
| PTGS1 | Cyclooxygenase-1, converts arachidonic acid to prostaglandins | Target of glucocorticoid suppression |
| PTGS2 | Cyclooxygenase-2, inducible enzyme for prostaglandin synthesis | Inflammation and cancer research |
| ALOX5 | Lipoxygenase, produces leukotrienes from arachidonic acid | Asthma and inflammatory disease models |
| ALOX12 | Lipoxygenase, produces 12-HETE | Platelet and macrophage studies |
| ALOX15 | Lipoxygenase, produces 15-HETE | Respiratory and immune research |
| FABP4 | Fatty acid-binding protein, transports arachidonic acid | Metabolic and inflammatory studies |
| SNAP23 | SNARE protein, mediates vesicle fusion | Milk secretion and mast cell degranulation |
| STX4 | Syntaxin-4, plasma membrane SNARE | Regulated secretion in epithelial cells |
| VAMP2 | Vesicle-associated membrane protein, SNARE | Vesicle fusion in secretory cells |
| PLA2G2A | Secretory phospholipase A2 | Inflammatory exudate and gut studies |
| PLA2G6 | Calcium-independent phospholipase A2 | Neurodegeneration and lipid metabolism |
| CAMP | Cyclic AMP, second messenger | Regulates macrophage secretion |
| PRKACA | Protein kinase A, cAMP-dependent | Modulates secretory pathways |
| NR3C1 | Glucocorticoid receptor | Mediates glucocorticoid suppression of arachidonate metabolism |
| ANXA1 | Annexin A1, regulates phospholipase A2 activity | Anti-inflammatory actions |
| SCP2 | Sterol carrier protein 2, lipid transfer | Arachidonic acid trafficking |
| CD36 | Fatty acid translocase | Uptake and secretion of fatty acids |
How Is arachidonate secretion Regulated?
Arachidonate secretion is regulated at multiple levels. Glucocorticoids suppress arachidonate metabolism and prostaglandin secretion, likely through inhibition of phospholipase A2 and cyclooxygenase expression. Cyclic AMP and divalent cations modulate macrophage lysosomal enzyme secretion, which is influenced by arachidonate metabolites. SNARE proteins, such as SNAP23 and syntaxin-4, control the vesicular fusion step required for regulated secretion. Additionally, the availability of arachidonic acid in breast milk is influenced by maternal diet and metabolic status, affecting infant gut microbiota. These regulatory mechanisms ensure that arachidonate secretion is appropriately tuned to physiological and pathological stimuli.
arachidonate secretion and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PLA2G4A | Inflammatory diseases, atopic dermatitis | Knockout mice, human keratinocyte cell lines |
| PTGS2 | Inflammation, cancer | Point mutation knock-in in cancer cell lines |
| ALOX5 | Asthma, allergic rhinitis | Overexpression in airway epithelial cells |
| PLA2G6 | Neurodegeneration (PLAN) | Knock-in mouse models, iPSC-derived neurons |
| SNARE proteins (SNAP23, STX4) | Milk secretion, mast cell degranulation | CRISPR knockout in mammary epithelial cells |
Atopic Dermatitis and Gut Dysbiosis
Breast milk-derived arachidonic acid can induce infant gut dysbiosis, which is associated with the onset of atopic dermatitis. This highlights how arachidonate secretion into milk and subsequent delivery to the infant gut can shape immune development and disease susceptibility.
Inflammatory and Gastroprotective Disorders
Arachidonate metabolites are key mediators of inflammation and gastroprotection. Glucocorticoids suppress arachidonate metabolism and prostaglandin secretion, which is relevant to inflammatory bowel disease and peptic ulcer treatments. Macrophage lysosomal enzyme secretion, regulated by arachidonate metabolites, contributes to tissue damage in chronic inflammation.
Alzheimer's Disease
Arachidonate metabolites affect the secretion of an N-terminal fragment of Alzheimer's amyloid precursor protein, suggesting a role for arachidonate secretion in amyloidogenic pathways. This links lipid signaling to neurodegeneration.
Respiratory Diseases
Human respiratory mucus secretion is influenced by arachidonate and its metabolites, implicating arachidonate secretion in airway diseases such as asthma and chronic obstructive pulmonary disease.
From arachidonate secretion-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PLA2G4A mediate arachidonate secretion in macrophages? | PLA2G4A knockout macrophage cell line (e.g., RAW264.7) |
| What is the role of a specific phosphorylation site in PTGS2? | Point mutation knock-in of PTGS2 in cancer cells |
| Can arachidonate secretion be tracked in live cells? | Tagged knock-in of FABP4 with fluorescent protein |
| Does overexpression of ALOX5 increase leukotriene secretion? | Overexpression of ALOX5 in airway epithelial cells |
| Is SNARE-mediated vesicle fusion required for arachidonate release? | Knockout of SNAP23 in mammary epithelial cells |
| Can CRISPR library screening identify novel regulators of arachidonate secretion? | Genome-wide CRISPR knockout library in secretory cell line |
How to Study the arachidonate secretion Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipidomics (LC-MS/MS) | Arachidonic acid and eicosanoid levels | Quantification of secreted lipids in supernatants |
| Fluorescent fatty acid imaging | Real-time secretion and trafficking | Live-cell imaging of arachidonate release |
| CRISPR knockout | Gene function in secretion | Loss-of-function studies in cell lines |
| CRISPR knock-in | Tagged protein localization | Tracking secretory vesicles |
| ELISA | Prostaglandin/leukotriene concentrations | High-throughput screening of secretion inhibitors |
| RNA-seq | Transcriptional changes in secretory genes | Pathway analysis after stimulation |
| Proteomics | Protein composition of secretory vesicles | Identification of novel secretion regulators |
| SNARE fusion assays | Vesicle fusion efficiency | Membrane fusion studies in vitro |
Lipidomics and Mass Spectrometry
Mass spectrometry-based lipidomics allows quantification of arachidonic acid and its metabolites in cell culture supernatants or tissues. This method can measure secreted arachidonate directly and profile downstream eicosanoids, providing a comprehensive view of the secretory process.
Fluorescent Fatty Acid Analogs and Imaging
Fluorescently labeled arachidonic acid analogs can be used to track secretion in live cells using confocal microscopy. This approach reveals real-time dynamics of arachidonate release and vesicular trafficking.
Genetic Knockout and Knock-in Models
CRISPR-Cas9 mediated knockout or knock-in of candidate genes (e.g., PLA2G4A, SNARE proteins) enables functional studies of arachidonate secretion. These models help establish causality between specific genes and the secretory phenotype.
Enzyme-Linked Immunosorbent Assays (ELISA) for Downstream Metabolites
ELISA kits for prostaglandin E2 or leukotriene B4 can indirectly measure arachidonate secretion by quantifying its stable metabolites in culture media. This is a cost-effective method for screening large sample sets.
How CRISPR Can Be Used to Study GO:0050482 arachidonate secretion
Knockout
CRISPR knockout of genes such as PLA2G4A or SNAP23 can abolish arachidonate secretion, confirming their essential roles. These models are used to study the contribution of specific genes to inflammatory responses and lipid mediator production.
Point Mutation
Point mutations can be introduced into genes like PTGS2 to mimic disease-associated variants or to abrogate catalytic activity. Such models help dissect the precise molecular mechanisms of arachidonate metabolism and secretion.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) into endogenous loci such as FABP4 allows real-time visualization of arachidonate trafficking and secretion in live cells. This approach provides spatial and temporal resolution of the secretory process.
Overexpression
Overexpression of enzymes like ALOX5 or PTGS2 can enhance arachidonate metabolite secretion, creating models to study hyperinflammatory states. These models are useful for drug screening and pathway analysis.
How EDITGENE Supports arachidonate secretion Research
Researchers studying arachidonate secretion-related genes often need to determine whether a candidate gene is causally involved in the secretory process or merely correlated with it. CRISPR-based genome editing provides the gold standard for establishing such causality, enabling precise knockout, point mutation, knock-in, or overexpression of target genes in relevant cell models.
Contact EDITGENE today to design your custom CRISPR model for arachidonate secretion research.
Frequently Asked Questions About arachidonate secretion
What is arachidonate secretion?
Arachidonate secretion (GO:0050482) is the controlled release of arachidonic acid from a cell or tissue, as defined by the Gene Ontology.
What genes are involved in arachidonate secretion?
Key genes include PLA2G4A, PTGS1, PTGS2, ALOX5, ALOX12, ALOX15, FABP4, SNAP23, STX4, and VAMP2, among others.
How is arachidonate secretion regulated?
It is regulated by glucocorticoids, cyclic AMP, divalent cations, and SNARE proteins, which control phospholipase activity and vesicle fusion.
What diseases are associated with arachidonate secretion?
Diseases include atopic dermatitis, inflammatory disorders, Alzheimer's disease, and respiratory diseases such as asthma.
What is the role of arachidonic acid in human milk?
Arachidonic acid in human milk influences infant gut microbiota and is associated with the onset of atopic dermatitis.
How can I study arachidonate secretion in the lab?
Methods include lipidomics, fluorescent imaging, ELISA for metabolites, and CRISPR knockout or knock-in models.
What is the GO ID for arachidonate secretion?
The GO ID is GO:0050482, under the biological_process ontology.
Which enzymes release arachidonic acid from membranes?
Phospholipase A2 enzymes, such as PLA2G4A, hydrolyze membrane phospholipids to release arachidonic acid.
Do glucocorticoids affect arachidonate secretion?
Yes, glucocorticoids suppress arachidonate metabolism and prostaglandin secretion.
Can CRISPR be used to study arachidonate secretion?
Yes, CRISPR knockout, knock-in, point mutation, and overexpression models are powerful tools to dissect the genetic control of arachidonate secretion.
Conclusion
Arachidonate secretion (GO:0050482) is a fundamental biological process that controls the extracellular availability of arachidonic acid, a key precursor to inflammatory and signaling lipids. Its regulation involves phospholipases, SNARE-mediated vesicle fusion, and hormonal inputs, and its dysregulation is linked to diseases ranging from atopic dermatitis to Alzheimer's disease. Understanding the genes and mechanisms underlying arachidonate secretion is essential for developing targeted therapies. EDITGENE provides comprehensive CRISPR services to accelerate this research.
References
- 1. Jiang S et al.. 2024. Association of breast milk-derived arachidonic acid-induced infant gut dysbiosis with the onset of atopic dermatitis.. Gut 74(1):45-57 PMID: 39084687
- 2. Duval D. 1990. Effect of glucocorticoids on arachidonate metabolism and prostaglandin secretion.. Rev Esp Fisiol 46(1):47-56 PMID: 2144360
- 3. Salem N Jr et al.. 2020. Arachidonic Acid in Human Milk.. Nutrients 12(3) PMID: 32121018
- 4. Truchet S et al.. 2014. Milk secretion: The role of SNARE proteins.. J Mammary Gland Biol Neoplasia 19(1):119-30 PMID: 24264376
- 5. Konturek SJ. 1990. Mechanisms of gastroprotection.. Scand J Gastroenterol Suppl 174:15-28 PMID: 2205898
- 6. Kaliner M et al.. 1986. Human respiratory mucus.. Am Rev Respir Dis 134(3):612-21 PMID: 3752717
- 7. Kinouchi T et al.. 1995. Arachidonate metabolites affect the secretion of an N-terminal fragment of Alzheimer's disease amyloid precursor protein.. Biochem Biophys Res Commun 209(3):841-9 PMID: 7733976
- 8. McMillan RM et al.. 1980. Regulation of macrophage lysosomal enzyme secretion: role of arachidonate metabolites, divalent cations and cyclic AMP.. J Cell Sci 44:299-315 PMID: 6255000
